Cangrelor
| CAS No. | 163706-06-7 | Cat. No. | BCP07743 |
| Name | Cangrelor | ||
| Synonyms | AR-C69931MX; AR C69931MX; ARC69931MX; AR-C 69931; Kengreal; AR-C69931XX; | ||
| Formula | C17H25Cl2F3N5O12P3S2 | M. Wt | 776.362 |
| Description | Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion. | ||
| Pathways | Ion Channel/Membrane Transporter Neuro Signaling Pathway GPCR/G Protein | ||
| Targets | P2 Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.